{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:54:01Z","timestamp":1762005241796,"version":"3.32.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2020.106016","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T18:30:36Z","timestamp":1589567436000},"page":"106016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012\u20132018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018\u20132019"],"prefix":"10.1016","volume":"56","author":[{"given":"Shio-Shin","family":"Jean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106016_bib0001","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0002","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jmii.2019.01.001","article-title":"Distribution of virulence genes in bacteremic methicillin-resistant Staphylococcus aureus isolates from various sources","volume":"52","author":"Wang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0003","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jmii.2018.06.007","article-title":"Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center","volume":"52","author":"Huang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jmii.2017.08.016","article-title":"The epidemiology, antibiograms and predictors of mortality among critically-ill patients with central line-associated bloodstream infections","volume":"51","author":"Kuo","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0005","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0006","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","article-title":"Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial","volume":"52","author":"Yuan","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2015.01.015","article-title":"Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013","volume":"82","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0009","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jfma.2015.07.011","article-title":"Risk factors for in-hospital mortality in patients with type 2 diabetes complicated by community-acquired Klebsiella pneumoniae bacteremia","volume":"114","author":"Huang","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic\u2013pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0011","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012\u20132014","volume":"86","author":"Karlowsky","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0012","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1517\/17425255.2014.972932","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil","volume":"10","author":"Merker","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0013","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0014","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0015","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1093\/jac\/dkv131","article-title":"Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"year":"2020","series-title":"Performance standards for antimicrobial susceptibility testing: thirtieth informational supplement M100-ED30","key":"10.1016\/j.ijantimicag.2020.106016_bib0016"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/eri.09.123","article-title":"Use of vancomycin pharmacokinetic\u2013pharmacodynamic properties in the treatment of MRSA infections","volume":"8","author":"Giuliano","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0018","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1128\/AAC.47.11.3554-3560.2003","article-title":"Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases","volume":"47","author":"Paterson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0019","doi-asserted-by":"crossref","first-page":"iii69","DOI":"10.1093\/jac\/dkr101","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jac\/dkw398","volume":"72","author":"Jean","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijantimicag.2014.12.023","article-title":"Pharmacokinetic\/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function","volume":"45","author":"Canut","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0022","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.01386-12","article-title":"Pharmacokinetics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection","volume":"57","author":"MacGowan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0023","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2011.01.017","article-title":"Ceftaroline: a comprehensive update","volume":"37","author":"Kaushik","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0024","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jgar.2014.02.006","article-title":"In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011)","volume":"2","author":"Flamm","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijantimicag.2014.12.014","article-title":"A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology","volume":"45","author":"Zhang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010275","article-title":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia","volume":"9","author":"Jean","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America","volume":"77","author":"Sader","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0028","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkv311","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme","volume":"71","author":"Karlowsky","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0029","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2016.06.017","article-title":"Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States hospitals: results from the AWARE Ceftaroline Surveillance Program (2012\u20132014)","volume":"86","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0032","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/2047-783X-15-12-554","article-title":"Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin","volume":"15","author":"Eckmann","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0033","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkw442","article-title":"Etest\u00ae versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study","volume":"72","author":"Cant\u00f3n","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0034","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1128\/AAC.02015-15","article-title":"Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia","volume":"59","author":"Abbott","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106016_bib0035","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:32:45Z","timestamp":1735673565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857920301795"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012\u20132018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018\u20132019","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106016"}}